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SUMMARY
BACKGROUND: Concurrent use of chemotherapy and twice-a-day hyperfractionated radiotherapy is 
an effi cacious scheme to control limited disease (LD) small-cell lung cancer (SCLC).
AIM: Our main objective was to estimate initial results in overall survival for patients with LD-SCLC 
treated with concomitant chemotherapy and hyperfractionated thoracic radiotherapy in routine prac-
tice. Response to treatment and toxicity were also assessed.
MATERIAL AND METHODS: Forty-nine patients with confi rmed LD-SCLC were treated at the Depart-
ment of Radiotherapy of the Hospital General de Catalonia (Spain) from December 1999 to February 
2007. The chemotherapy regimen was cisplatin (80 mg/m2) on day 1 and etoposide (100 mg/m2) on 
days 1, 2, and 3, every 21 day. The target dose to the tumor volume was 45 Gy. Prophylactic cranial 
irradiation (PCI), consisting of 30 Gy delivered in 15 fractions, was prescribed for all patients with a 
response rate >75% (23 of 30 patients). 
RESULTS: Median follow-up was 12 months (range, 6-58 months) and median overall survival was 
28.9 months. Two-year and 4-year survival rates were 56.4% and 30.1%, respectively. At 2 years, 
specifi c survival, local control, and systemic control were 64.2%, 88.8%, and 46.8%, respectively. 
Myelotoxicity and oesophagitis were the most severe toxicities.
CONCLUSIONS: The combined schedule – hyperfractionated irradiation plus concurrent chemotherapy 
– can be applied in routine practice in the context of early radiotherapy, which is considered standard 
treatment, with acceptable toxicity and similar results to those described in the literature.
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BACKGROUND
Small-cell lung cancer (SCLC) accounts for 
approximately 15% of the total lung cancers 
diagnosed around the world [1]. Nearly 33% of 
these are categorized as limited disease (LD-
SCLC) based on their clinical confi nement to 
a single hemithorax, regional lymph nodes, 
which can be treated in a reasonable radia-
tion fi eld [2]. Meta-analyses by Pignon et al. 
[3] and Warde and Payne [4] found that com-
bined chemoradiotherapy produces a modest 
but signifi cant increase in survival and also 
achieves better local control compared to che-
motherapy alone. 
External beam radiation is accepted as an 
integral part of the treatment of LD-SCLC but 
controversies remain regarding dose, tim-
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ing, and fractionation. These controversies 
have been extensively discussed in recent re-
views by Fried et al. [5] and De Ruysscher et 
al. [6], both of whom conclude that available 
evidence indicates that 2- and 5-year survival 
rates of patients with LD-SCLC favour the use 
of early chest radiotherapy, with a signifi cant 
difference in survival if the overall treatment 
time of the chest radiation is less than 30 days 
and when hyperfractionated radiotherapy and 
platinum-based chemotherapy are used.
Twice daily fractionation is theoretically 
advantageous for malignancies such as SCLC, 
which are characterized by rapid cell prolifer-
ation. The effect of hyperfractionation in LD-
SCLC has been evaluated in two trials. Tur-
rissi et al. [7] carried out a randomized trial 
of concurrent chemoradiotherapy with 45 Gy 
radiation delivered either once or twice daily 
during the fi rst cycle of cisplatin and etopo-
side. The authors reported a signifi cant in-
crease in 2- and 5-year overall survival rates 
for the hyperfractionated arm. In a trial car-
ried out by Bonner et al. [8], radiotherapy was 
delayed until the start of the fourth cycle of 
cisplatin and etoposide and patients random-
ized to the hyperfractionated arm were given 
a midcourse break of 2.5 weeks (split-course 
radiotherapy). However, the authors found 
no benefi t in overall survival with the use of 
twice-daily radiation.
AIM
The main objective was to estimate initial re-
sults in overall survival of patients with LD-
SCLC treated with concomitant chemotherapy 
and hyperfractionated thoracic radiotherapy 
in daily practice at a single institution (Hospi-
tal General de Catalunya, Spain). Response to 
treatment and toxicity were also assessed.
MATERIAL AND METHODS
After the results of the Turrissi et al. study 
were published in October 1999, we began 
treating patients with the same chemoradio-
therapy regimen in our clinical practice. Be-
tween December 1999 and February 2007, 49 
patients with LD-SCLC were treated at the 
Department of Radiotherapy of the Hospital 
General de Catalunya. In the present article 
we present the results of the fi rst 30 patients, 
treated up to March 2005.
 Pretreatment diagnostic and staging pro-
cedures included complete history and physi-
cal examination, full blood count, blood chem-
istry, chest X-ray, fi breoptic bronchoscopy, 
radionuclide bone scanning, and computed to-
mographic scan of the thorax including the up-
per abdomen and central nervous system. No 
positron emission tomography (PET) was per-
formed. Patients with contralateral hilum or 
supraclavicular nodal disease were excluded 
from hyperfractionation regimen treatment.
Histological diagnosis of SCLC was based 
on criteria from the World Health Organiza-
tion (WHO) [9] and stage classifi cation was 
based on the recommendation of the Veterans 
Administration Lung Group (VALG), including 
supraclavicular nodes and pleural effusions 
[10]. General inclusion requirements were as 
follows: adequate organ function, including 
leucocyte count >3000/mL, absolute granu-
locyte counts >1500/mL, platelets >100,000, 
and creatinine <1.5 mg/dL. Additional inclu-
sion criteria were hepatic parameters (espe-
cially transaminases) within normal limits 
and forced expiratory volume in one second > 
1500 mL.  
The chemotherapy regimen consisted of cis-
platin (80 mg/m2) given on day 1 and etoposide 
(100 mg/m2) on days 1, 2 and 3. This regimen 
was then repeated every 21 days for a total of 4 
to 6 cycles depending on performance status. 
Radiotherapy, given concomitantly to che-
motherapy, commenced as soon as it was fea-
sible: 22 patients received radiotherapy during 
the third cycle, 7 during the second, and 1 dur-
ing the fi rst cycle. Patients were given 2 frac-
tions/day of 1.5 Gy each, separated by an in-
terval of 6 hours, 5 days per week for 3 weeks. 
The aim was to deliver a dose of 45 Gy to the 
tumour volume. Two patients received 50.5 Gy 
and one 54.5 Gy to compensate for interrup-
tions in the radiotherapy delivery. The plan-
ning target volume (PTV) included all of the 
tumour area defi ned by the CT scan as well as 
the bilateral mediastinal nodes–including one 
lymph echelon beyond the involved nodal area, 
and homolateral hilum. The contralateral hi-
lum and supraclavicular nodes were excluded 
from the PTV. Anteroposterior/posteroante-
rior fi elds were used in the two fractions given 
during the fi rst week. In the second and third 
weeks of administration, the second fraction 
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was given through oblique fi elds so as to pre-
clude irradiation of the spinal cord to avoid 
exceeding 36 Gy to that risk organ.
Response assessment took place approxi-
mately 4–6 weeks after completion of the fi nal 
chemotherapy cycle and included complete 
history and physical exam, full blood analy-
sis, and chest CT scan. PCI, consisting of 30 
Gy delivered in 15 fractions, was prescribed 
for all patients who achieved a response >75% 
and was administered 6 weeks after the last 
chemotherapy cycle. Toxicity was scored us-
ing the CTCAE scale (version 3.0) [18].
RESULTS
Patient Characteristics:
Table 1 shows patient characteristics. Males 
were clearly predominant (28:2), with a me-
dian age of 57.8 years (range: 35–75). Most 
patients (20 patients; 67%) had a Karnofsky 
index in the range 90%–100%, while the re-
maining patients (10 cases; 33%) had a Kar-
nofsky index in the range 70%–80%. 
Age: 
Range (years)
Median (years)
35–75
57.8
Sex: 
Male:
Female:
28 patients
2 patients
Karnofsky status
100%
90%
80%
70%
# of patients
1
19
9
1
Table 1. Patient characteristics (N=30)
in nearly all cases (29 patients) with only one 
exception: 1 patient received mixed treatment 
(linear accelerator and cobalt unit).
The total dose was 45 Gy in 27 patients. 
However, 3 patients received a higher dose 
(in 2 cases, 50.5 Gy and in 1 case 54.5 Gy) to 
compensate for interrupted radiotherapy sec-
ondary to machine breakdowns. The median 
overall treatment time was 21.2 days (range, 
18–27 days).
Most patients (28 of 30) underwent cispla-
tin-based chemotherapy, although carboplatin 
was used in 2 cases.
Acute Toxicity:
Myelotoxicity and oesophagitis were the 
most severe toxicities (Table 2).
Severe anaemia requiring blood transfu-
sion was present in 3 patients (10% G3–G4). 
Compliance with radiochemotherapy 
treatment:
For logistical reasons, most patients began ra-
diotherapy treatment during the second and 
the third cycle of chemotherapy. This delay 
was attributable, in most cases, to waiting 
lists in the radiotherapy department. As a re-
sult, 22 patients received radiotherapy during 
the third cycle, 7 patients during the second, 
and only 1 patient during the fi rst cycle. Treat-
ment was delivered with a linear accelerator 
Anaemia
  G0
  G1
  G2
  G3
  G4
# of patients
13
12
2
2
1
Leucopenia
  G0
  G1
  G2
  G3
  G4
# of patients
15
4
5
3
3
Neutropenia
  G0
  G1
  G2
  G3
  G4
# of patients
16
3
2
4
5
Thrombocytopenia
  G0
  G1
  G2
  G3
  G4
# of patients
22
0
4
1
3
Oesophagitis
  G0
  G1
  G2
  G3
  G4
# of patients
2
11
14
3
0
Table 2. Acute Toxicity:
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G3 leucopenia occurred in 3 patients, while 3 
others experienced G4 leucopenia (20% of pa-
tients with severe leucopenia). G3 neutropenia 
was detected in 4 patients, and 5 others had 
G4 (30% severe neutropenia). Concomitant 
infection was documented in 7 patients, all of 
whom responded satisfactorily to intravenous 
antibiotic therapy and haematopoietic growth 
factors. G3 thrombocytopenia occurred in 1 
patient and G4 in 3 patients (13.3% severe leu-
copenia). No toxic deaths occurred.
During chemoirradiation, the most common 
grade of oesophagitis was G2, which occurred 
in 14 patients (48%). Only 3 patients presented 
G3 oesophagitis, treated with an endoscopic 
gastric tube and major analgesia. No G4 oe-
sophagitis occurred. 
Several different factors–including length 
of oesophagus irradiated, overall treatment 
time, and total number of neoadjuvant che-
motherapy cycles–were studied to determine 
if there was any association with acute oe-
sophagitis. None of these variables were found 
to be signifi cant except for the use of 2 or more 
neoadjuvant chemotherapy cycles, in which 
patients seemed to develop less acute oe-
sophagitis. Five patients developed G2 weight 
loss, while most experienced G1 (14 patients). 
Three patients had G1 acute pneumonitis at 
the end of radiotherapy.
Response
All 30 patients completed the recommended 
treatment. Of these, 7 showed a partial re-
sponse of less than 75%. The remaining pa-
tients (23 cases; 76.6%) achieved a partial (> 
75%) or complete response and all of these 
underwent PCI. No cases of disease progres-
sion occurred after radiochemotherapy was 
applied. The total PCI dose was as follows: 19 
patients received 30 Gy in 15 fractions, 2 were 
given 32 Gy, and 2 underwent 36 Gy to com-
pensate for the delay (> 6 months) between 
diagnosis and PCI.
Chronic toxicity
Nine patients developed G1 clinical oesophagi-
tis that was well controlled with symptomatic 
management. Lung toxicity was present in 
different grades: G1 in 5 patients, G2 in 5 pa-
tients, G3 in 1 patient, and G4 in 2 patients. 
Additionally, chronic encephalitis–confi rmed 
by clinical examination and cerebral MRI 
changes–was diagnosed in 2 patients.
Patterns of recurrence
The site of fi rst recurrence was documented in 
18 patients. Recurrences were local alone (in-
fi eld) in 3 patients, local alone (out-of-fi eld) in 
1 patient, systemic failure alone in 13 patients, 
and systemic and local out-of-fi eld in 1 patient. 
Brain metastases occurred in 7 patients as a 
fi rst recurrence, 4 of whom had previously un-
dergone PCI.
Survival
With a median follow-up of 12 months (range, 
6-58), the median survival was 28.9 months. 
Overall survival at 2 and 4 years was 56.4% 
and 30.1%, respectively (Figure 1). At 2 years, 
specifi c survival was 64.2% (Figure 2), local 
control was 88.8% (Figure 3), and systemic 
control was 46.8% (Figure 4)
DISCUSSION
Our treatment schedule, based on the ran-
domised trial by Turrissi et al. [7], was ap-
plied as part of routine practice in the year 
2000, in an attempt to reproduce the most ef-
fective arm of that study.  
We encountered several diffi culties in ap-
plying a regimen identical to that described 
by Turrissi. First, due to waiting lists, most 
patients began radiotherapy concomitant 
with the second (7/30 patients) or third che-
motherapy cycle (22/30 patients). As a result, 
treatment began on day +21 and day +42. In 
addition, the defi nition of early and late radio-
therapy is a subject of intense debate. Fried et 
al. [5] found that chest radiotherapy delivered 
within the fi rst 9 weeks after starting chemo-
therapy conferred a survival benefi t at 2 years. 
In contrast, De Ruysscher and colleagues [6], 
who defi ned early radiotherapy as beginning 
within 30 days after the start of chemotherapy, 
found early treatment to be associated with a 
better 5-year survival rate, especially if the 
overall treatment time of chest radiotherapy 
is less than 30 days. A review carried out by 
Stuschke et al. [11] showed that scheduling of 
radiotherapy and chemotherapy is important 
in the treatment of a fast proliferating tumour 
such as SCLC and prolonged overall treatment 
with sequential radiochemotherapy should be 
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avoided. In our case, radiotherapy was deliv-
ered concomitantly either with the second or 
third cycle, unlike the study by Turrissi, in 
which radiotherapy treatment was concurrent 
with the fi rst cycle.
The second diffi culty was related to the fact 
that, in contrast to Turrissi, we routinely ex-
cluded contralateral disease and supraclavicu-
lar nodes because 2.5D radiotherapy (2 dimen-
sions in different slices) was delivered to the 
PTV and it was extremely diffi cult to ensure 
perfect coverage in these cases. Given the rap-
id shrinkage of the tumour during the course of 
chemotherapy, the GTV became considerably 
smaller at the beginning of the second or third 
chemotherapy cycle. As a result, a smaller 
lung volume and shorter length of oesophagus 
was irradiated than in Turrissi et al. A study 
from the Southwest Oncology Group (SWOG) 
[12] showed no difference in recurrence rates 
between patients randomized to receive wide-
fi eld radiation (pre-chemotherapy target vol-
ume) and those who received reduced fi eld 
(post-chemotherapy target volume) radiation.
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Fig. 1. Overall survival
Fig. 2. Specifi c survival 
Fig. 3. Local control 
Fig. 4. Systemic control
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Despite the limited number of patients (30) 
in our study, median survival was 28.9 months, 
similar to the results (23 months) reported by 
Turrissi. The survival rate was good: 56.4% at 
2 years and 30.1% at 4 years, similar to rates 
reported by Turrissi (41% at 2 years and 26% 
at 5 years).
Our series showed modest toxicity. Hae-
matological toxicity included G3–G4 anae-
mia in 3 patients (10%), G3–G4 leucopenia 
in 6 patients (20%), G3–G4 neutropenia in 9 
patients (30%), and G3–G4 thrombocytope-
nia in 4 patients (13%). In general, patients in 
our series showed less haematological toxicity 
than that reported by Turrissi, probably due 
to the different doses of etoposide used (100 
mg/m2 versus 120 mg/m2) and smaller radio-
therapy fi elds that included fewer vertebrae. 
This may also explain the limited number of 
severe oesophageal toxicities: no patients de-
veloped G4 oesophagitis, while only 3 devel-
oped G3 oesophagitis, in contrast to Turrissi, 
where 5% and 27%, respectively, of patients 
developed G4 or G3 oesophagitis. Finally, only 
3 patients experienced either G3 (1 patient) 
or G4 (2 patients) chronic pneumonitis, the 
most debilitating toxicity. Other authors [13, 
14] have reported similar toxicities using hy-
perfractionated radiotherapy and concomitant 
chemotherapy in daily practice.
A meta-analysis [15] found that PCI was 
associated with a 5.4% increase in overall 
survival at 3 years in patients who achieved 
a complete response. In our series, patients 
who achieved a partial (> 75%) or complete re-
sponse (23/30 patients) underwent PCI. After 
PCI, only 4 of these 23 patients experienced a 
relapse in the brain. Although PCI is delivered 
after completion of chemotherapy and ideally 
no longer than 6 months after diagnosis, the 
optimal dose has not yet been clearly estab-
lished. The standard seems to be 25 Gy in 10 
fractions, although 36 Gy delivered in 18 frac-
tions has been shown to have a lower brain re-
lapse rate [19]. We used 30 Gy in 10 fractions, 
a schedule with a biologically equivalent dose 
(using an alpha/beta ratio of 3 for neuronal tis-
sue) to the accepted standard in place at the 
beginning of 2000. Evidence from trials with 
up to 2 years of follow-up data shows that PCI 
does not cause signifi cant late neurotoxic-
ity or other adverse effects such as emotional 
distress and deteriorated physical condition. 
Chemotherapy can contribute to neurologi-
cal dysfunction in some SCLC patients, and 
nearly 40% of these patients have neurologi-
cal impairment prior to PCI [16, 17]. Chronic 
encephalitis – confi rmed by clinical examina-
tion and changes on the brain MRI – was diag-
nosed in 2 patients in our practice. Neurotox-
icity was not evaluated by neuropsychometric 
testing.
Excellent local control is another advantage 
of hyperfractionated treatment. In our series, 
local control was 88.8% at 2 years and the 
main pattern of fi rst recurrence was systemic 
(14 patients; 46.6%). New approaches in stag-
ing, such as PET CT scans, can help to defi ne 
more clearly those patients that have only lim-
ited disease. In this way, we may infl uence and 
improve systemic control.
CONCLUSIONS
The Turrissi schedule can be applied in rou-
tine practice in the context of early radio-
therapy concomitant to chemotherapy, which 
is considered standard treatment, and simi-
lar results can be achieved. Longer follow-up 
needs to be done, especially considering the 
number of patients treated at our institution 
(49 by February 2007). The optimal dose is 
already being explored in a current phase III 
(Convert) trial comparing accelerated twice-
daily radiotherapy (45 Gy) to once-daily radio-
therapy up to 66 Gy concurrently with cispla-
tin-etoposide during the second cycle.
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